The company plans to share the first-in-human safety data from the Phase 2/3 SIGLEC trial evaluating intravitreal AVD-104.
Aviceda Therapeutics has shared its upcoming presentations at the American Society of Retina Specialists (ASRS) and the OIS Retina Innovation Summit Meetings. These presentations will focus on the company’s lead ophthalmic clinical asset, AVD-104, a novel glycan-coated nanoparticle for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)1.
Mohamed Genead, MD, Chief Executive Officer & Co-Founder, Aviceda Therapeutics said in the press release that the company is looking forward to sharing these insights, “We are excited about Aviceda's presence at ASRS this year. AVD-104 was engineered with dual mechanism of action to target both the cellular immune dysfunction and complement implicated in AMD progression. We look to usher in a new paradigm for safer and effective treatment of GA associated with AMD.”1
Aviceda’s presentations are as follows:
July 27, 2023 – OIS Retina Innovation Summit, Seattle, WA
July 29, 2023 – American Society of Retina Specialists Annual Meeting, Seattle, WA
“I am excited to present the first-in-human safety data from the Phase 2/3 SIGLEC trial evaluating intravitreal AVD-104. This drug may the first next generation treatment for GA with its dual mechanisms of action that attack critical inflammatory pathways by inhibiting activated retinal macrophages and repolarizing them to their resolution states while also inhibiting amplification of the complement cascade,” said Regillo in the news release1.